Log In
Print
BCIQ
Print
Print this Print this
 

gantenerumab (R1450, RG1450)

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionHuCAL-derived human mAb targeting beta amyloid
Molecular Target Beta amyloid
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation

Partner

Chugai Pharmaceutical Co. Ltd.; MorphoSys AG


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today